Medidata Medidata

Clinical Trials in the Age of Coronavirus

Clinical Trials 101

Clinical Trials In The Age of Coronavirus
Source: Medidata.com

The following content is text taken from the above infographic and provided to you in an easy copy and paste format. Please feel free to use it in any writing that references this article.

Share this infographic on your site or within a blog post: (Copy Paste This Code)

<a href="https://www.medidata.com/en/clinical-trials-covid19-infographic"><img src="http://media-s3-us-east-1.ceros.com/medidata/images/2020/06/26/6efb7b6d0547f854913d3f12929ae88b/medidata-solutions-the-end-of-covid-19final.png " alt="Clinical Trials In The Age of Coronavirus" width="500" border="0" /></a><br />Source: <a href="https://www.medidata.com">MediData.com</a>

To end the COVID-19 pandemic will require cutting-edge clinical trial technology and testing 

In the U.S., it typically takes a new drug 12 years to reach the market

      • Research & Development: 3.5 years
      • Investigational New Drug Application: 30 days
      • Clinical Trials: 6 years
        • Phase 1: 1 year
        • Phase 2: 2 years
        • Phase 3: 3 years
      • New Drug Application: 2.5 years

Of all the drugs that enter clinical trials, just 10% are approved — The fastest way to find a cure for COVID-19 is to test as many options as possible 

Challenges For Clinical Trials

  • Low Enrollment: More than two million patients are needed for clinical trials every year
      • Just 5% of the patients recruited to participate in a trial enroll
      • 46 million patients are recruited in order to the 2 million needed — That’s more than the population of Spain
  • Lack Of Diversity: Both drugs and diseases (including COVID-19) may affect diverse populations differently
    • African Americans make up less than 5% of trial participants, but 20% of the U.S. population
      • Similar disparities exist among Asian and Native American populations
      • Socioeconomic barriers and a history victimization in medical experiments may contribute to minorities unwillingness to participate in clinical trials
  • COVID-19: The global pandemic has also impacted trials of experimental drugs for other diseases
      • 69% of ongoing clinical trials and 78% of new trials have been affected by the pandemic
      • Researchers’ top concern is their ability to continue recruiting and enrolling patients
  • Adaptive Trials: A Faster Path?
    • Test multiple treatments at one time and adapt as new data emerges
    • Increases number of participants given the most promising treatments
    • Enabled by advance algorithms that maintain the integrity of the trial data
    • REMAP-CAP is an ongoing adaptive trial for community acquired pneumonia, designed to be ready to fight new and emerging diseases
      • Already assessing multiple COVID-19 treatments
  • How Soon Could We See A Cure?
    • In 2003, developing an H1N1 vaccine took 5-6 months
      • Knowledge and infrastructure for flu vaccines was already in place
      • Clinical trial requirements were brief or waived entire based on extensive study of existing seasonal flu vaccines
    • The fastest vaccine developed from scratch was the mumps vaccine — Taking just 4 years
      • A COVID19 vaccine may be developed much faster by
        • Building on knowledge gained from similar outbreaks like SARS-1
        • Using more advanced technology and trial mechanisms

Interested in joining a trial? Go to clinicaltrials.gov or contact a patient advocacy group and start a conversation with your doctor